FDA approves Botox for treatment of overactive bladder

Author(s):

On Jan. 18, 2013, the U.S. Food and Drug Administration (FDA) approved the use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who can’t use or don’t adequately respond to anticholinergics. Botox’s safety and effectiveness for this new indication were established in two clinical trials of 1,105 patients with symptoms of overactive bladder. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here